Hypertension and new treatment approaches targeting the sympathetic nervous system

Area of Science:

• Cardiology
• Nephrology
• Medical Devices

Background:

• Increasing prevalence of primary and resistant hypertension in the US.
• Many patients fail to achieve guideline-directed blood pressure (BP) goals despite pharmacotherapy.
• Uncontrolled BP significantly increases cardiovascular morbidity, mortality, and kidney disease progression.

Purpose of the Study:

• To review the challenges in hypertension management.
• To highlight the limitations of current pharmacotherapy in controlling the sympathetic nervous system (SNS).
• To explore emerging device-driven therapeutic approaches for hypertension.

Main Methods:

• Review of current literature on hypertension pharmacotherapy and its limitations.
• Analysis of the role of the sympathetic nervous system (SNS) in hypertension.
• Examination of recent investigations into device-driven therapies such as renal denervation and baroreflex activation therapy.

Main Results:

• Pharmacotherapy often fails to effectively inhibit the SNS, a key factor in hypertension.
• Tolerability of SNS-targeting antihypertensives is moderate.
• Device-driven approaches show promising but sometimes conflicting results.

Conclusions:

• Inadequate control of hypertension remains a significant clinical challenge.
• Device-driven therapies represent a promising area for managing resistant hypertension.
• Further research is needed to clarify the efficacy and consistency of novel device-based interventions.